Swedish pre-clinical biomarker assay company Offspring Biosciences and US spatial biology and biomarker analytics company Flagship Biosciences have announced a strategic partnership.
The partnership aims to further advance precision drug development with a complete biomarker offering from discovery to companion diagnostics development, the companies state.
“Together, Flagship Biosciences and Offspring Biosciences will provide a seamless and comprehensive suite of preclinical and clinical services, empowering our clients to accelerate drug development and bring lifesaving therapies to patients faster,” says Anders Dahlstrand, CEO of Offspring Biosciences.
The partnership allows both companies to leverage each other’s expertise in pre-clinical and clinical trial assays, to provide their drug development partners a full end-to-end solution with a North American and European footprint, they state.
“We are very excited to partner with the expert team at Offspring,” says Flagship Biosciences CEO Trevor Johnson. “With their vast experience developing innovative biomarker and assay solutions, we are very confident that our combined offerings will bring a unique and valuable combination of translational and clinical capabilities to our development partners.”
Photo of Trevor Johnson and Anders Dahlstrand
